{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"53"},{"groupId":"OG002","value":"55"}]}],"title":"Any AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"39"}]}],"title":"Any SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"55"}],"units":"Participants"}],"description":"An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury.","groups":[{"description":"Participants received dabrafenib 150 mg gelatin capsules BID.","id":"OG000","title":"Part C: Dabrafenib 150 mg"},{"description":"Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.","id":"OG001","title":"Part C: Dabrafenib 150 mg + Trametinib 1 mg"},{"description":"Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.","id":"OG002","title":"Part C: Dabrafenib 150 mg + Trametinib 2 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"ATP Population","reportingStatus":"POSTED","timeFrame":"From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)","title":"Part C (Randomized): Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)","type":"PRIMARY","unitOfMeasure":"Participants"}